Plasmocin.com - Activity Spectrum

ACTIVITY activity spectrum | association with Pen/Strep | cytotoxicity

ANTIMICROBIAL ACTIVITY SPECTRUM OF PLASMOCIN:

The in vitro antimicrobial activity of Plasmocin tested against different mycoplasma, Gram+ bacteria, Gram– bacteria and fungi is reported in the following table.
To eradicate mycoplasmal contamination, using Plasmocin at 25 µg/ml for two weeks is advised.

Sensitive under 1 µg/ml	Sensitive from 0.5 to 25 µg/ml	Resistant
Slow growing microbial contaminants	Fast growing microbial contaminants

Mollicutes: mycoplasmas & acholeplasmas M. arginini ATCC 23838 M. fermentans ATCC 19989 M. hyorhinis ATCC 17981 M. bovis NCTC 10131 M. orale ATCC 23714 A. laidlawii ATCC 23206	Bacteria: strains from ATCC or isolated from clinical or environmental samples Staphylococcus aureus ATCC 25923 Enterococcus faecium Bacillus subtilis Lactobacillus casei ATCC 393 Lactobacillus plantarum Escherichia coli Enterobacter cloacae Citrobacter freundii Klebsiella pneumoniae Morganella morganii Pseudomonas aeruginosa (wild strains)	Yeasts: strains from ATCC or isolated from clinical samples Candida albicans Candida tropicalis Candida parapsilosis Saccharomyces cerevisiae ATCC 32119 Molds

ASSOCIATION with PEN / STREP :

Plasmocin is compatible with penicillin/streptomycin solutions. Plasmocin can be added to penicillin / streptomycin preparations in order to expand the activity spectrum of this mixture, especially against mycoplasmas.

CYTOTOXICITY :

Various cell-types have been propagated in Plasmocin-supplemented media without apparent cytotoxic effect:

Adenocarcinoma
Breast cancer
Human colon carcinoma
Human glioblastoma
Leukemia
Lung carcinoma
Melanoma, skin carcinoma
Pancreatic cancer
Prostate carcinoma
Chondrocytes
Fibroblasts, human foreskin fibroblasts
Human adrenal cortex
T-cell clones
Adult stem cell lines
Mouse embryonic stem cells
Rat pituitary
Bi-color damselfish cell lines
Hybridomas

Examples of cell lines propagated in Plasmocin™ supplemented media

Cell lines propagated with a permanent adjonction of Plasmocin™ at 2.5µg/ml
293 HeLa MCF-7 HepG2 PC-3 K562 Jurkat B16 C2C12 PC 1.0 C6	Tranformed primary embryonal kidney Epitheloid carcinoma Breast adenocarcinoma Hepatocellular carcinoma Prostate adenocarcinoma Chronic myelogenous leukemia Acute T cell leukemia Melanoma Muscle myoblast Pancreas adenocarcinoma Glial tumor	Human Human Human Human Human Human Human Mouse Mouse Hamster Rat

Cell lines successfully treated with Plasmocin™ at 25µg/ml for 2 weeks.
MF61 MF116 RF-48 RF-1 COS-1 COS-7 BALB/c NIH/3T3	Hybridoma(anti ovarian carcinoma) Hybridoma(anti ovarian carcinoma) Metastatic gastric adenocarcinoma Gastric adenocarcinoma Kidney, SV40 transformed Kidney, SV40 transformed Fibroblast Embryo,contact inhibited	Human Human Human Human Monkey Monkey Mouse Mouse

To date, no data on toxicity of Plasmocin to cell lines being treated have been reported.
However, it must be noted that at high concentrations of Plasmocin, slowdown of cell growth rate may be observed. Nevertheless, when Plasmocin is removed from culture medium or when Plasmocin is used at a lower concentration, cells rapidly get back to their normal growth rate.